• OLAYINKA S. ILESANMI Department of Community Medicine, College of Medicine, University of Ibadan, Oyo State, Nigeria, Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria
  • AANUOLUWAPO A. AFOLABI Department of Community Medicine, College of Medicine, University of Ibadan, Oyo State, Nigeria
  • OLUWATOSIN E. FAKAYODE Department of Public Health, State Ministry of Health, Ilorin, Kwara State, Nigeria


Objective: This report aimed to determine the immediate effect of the IPC training on the knowledge and role of patent medicine vendors (PMV) in the COVID-19 outbreak response in Nigeria.

Methods: We conducted a quasi-experimental study before and after the IPC training among 1076 PMV in Ilorin, Kwara state, Nigeria. Data analysis was done using SPSS version 23. Eight questions were asked, for which each was assigned a score of “1”. Participants who had scored<50% were categorized as “Fail”, while those with scores ≥50% were categorized as “Pass” in both the pre and post-tests. The Chi-square test was used to test for the association between sociodemographic characteristics and performance of respondents in the pre-and post-IPC knowledge results, and paired t-test to test for significant differences between the pre and post-tests mean scores. The level of significance was set at p<0.05 for all statistical tests.

Results: The mean age of the 1076 respondents was 37.06±10.96, 463(43%) passed the pre-test, while 617 (57.3%) passed the post-test. The mean pre-test IPC training score was 3.1310±1.5631, while the mean post-test IPC training score was 3.7351±1.6028 (t=-11.337, p=<0.001). In all, 617(57.3%) scored higher in posttest. Overall, 560 (92.41%) identified community sensitization and health education on COVID-19 preventive measures as roles of PMV.

Conclusion: Regular trainings on COVID-19 preventive practices among PMV should be conducted. PMV should be empowered to sensitize and educate their clients on the prevention of COVID-19.

Keywords: COVID-19, Patent medicine vendors, Infection prevention and control, COVID-19 prevention and control, Nigeria


Download data is not yet available.


1. Ilesanmi OS, Akande A, Afolabi AA. Overcoming COVID-19 in West African countries: Is herd immunity an option? Pan Afr Med J 2020;35:103.
2. Cherumanalil JM, Thayyil J. Pharmacoloical treatments of COVID-19: a review. Asian J Pharm Clin Res 2020;13:16-22.
3. Sasmi MB, Jose M, Kuttichira P. Current therapeutic options for coronavirus disease-2019-a pharmacological review. Asian J Pharm Clin Res 2020;13:42-50.
4. Quadrie ZL, Wani Shahid UD, Gautam SP, Khan KA. Outbreak, epidemiology, therapeutics and prevention of coronavirus disease-2019: a review. Int J Curr Pharm Res 2020;12:1-4.
5. Ilesanmi O, Afolabi A. Perception and practices during the COVID-19 pandemic in an urban community in Nigeria: a cross-sectional study. Peer J 2020;8:e10038.
6. European Centre for Disease Control. COVID-19 situation update worldwide; 2020. Available from: [Last accessed on 05 Nov 2020]
7. Adeloye D, David RA, Olaogun AA, Auta A, Adesokan A, Gudanya M, et al. Health workforce and governance in Nigeria. Hum Res Health 2017;15:32.
8. Worldometer. Nigeria Population; 2020. Available from: [Last accessed on 21 Oct 2020]
9. Ilesanmi OS, Afolabi AA. Home-based care in the management of COVID-19 in Nigeria. Ibom Med J 2021;14.
10. Beyeler N, Liu J, Sieverding MA. Systematic review of the role of proprietary and patent medicine vendors in healthcare provision in Nigeria. PLoS One 2015;10:e0117165.
11. Durowade KA, Bolarinwa OA, Fenenga CJ, Akande TM. Operations and roles of patent and proprietary medicine vendors in selected rural communities in edu local government Area, Kwara State, North-Central Nigeria. J Com Med Prim Health Care 2018;30:75-89.
12. Treleaven E, Liu J, Prach LM, Isiguzo C. Management of pediatric illnesses by patent and proprietary medicine vendors in Nigeria. Malar J 2015;14:232.
13. Liu J, Prach LM, Treleaven E, Hansen M, Anyanti J, Jagha T, et al. The role of drug vendors in improving basic health-care services in Nigeria. Bull World Health Organ 2016;94:267–75.
14. Prach LM, Treleaven E, Isiguzo C, Liu J. Care-seeking at the patent and proprietary medicine vendors in Nigeria. BMC Health Serv Res 2015;15:1-12.
15. Sieverding M, Liu J, Beyeler N. Social support in the practices of informal providers: the case of patent and proprietary medicine vendors in Nigeria. Soc Sci Med 2015;143:17–25.
16. Ilesanmi OS, Afolabi AA. In search of the true prevalence of COVID-19 in Africa: Time to involve more stakeholders. Int J Health Sci 2020:e108105.
17. City Population–statistics, maps, and charts. Kwara state in Nigeria. Available from: adm1id=NGA024. [Last accessed 21 Oct 2020]
18. Britannica. Kwara state, Nigeria. Available from: [Last accessed on 21 Oct 2020].
19. Ilesanmi OS, Afolabi AA. Six months of COVID-19 response in Nigeria: lessons, challenges, and way forward. JID Health 2020;3(Special 1):198-200.
20. Auta A, Omale S, Folorunsho TJ, David S, Banwat SB. Medicine vendors: self-medication practices and medicine knowledge. N Am J Med Sci 2012;4:24–8.
86 Views | 109 Downloads
How to Cite
ILESANMI, O. S., A. A. AFOLABI, and O. E. FAKAYODE. “PATENT MEDICINE VENDORS’ PREPAREDNESS AND RESPONSE FOR THE PREVENTION AND CONTROL OF COVID-19 INFECTION IN A NORTH-CENTRAL STATE IN NIGERIA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 12, Dec. 2020, pp. 80-84, doi:10.22159/ijpps.2020v12i12.40097.
Original Article(s)